The AlphaLISA® SureFire® Ultra™ Total CHK2 assay is a sandwich immunoassay for quantitative detection of total CHK2 in cellular lysates using Alpha Technology.
This kit has been pre-validated for use in combination with Pelago Bioscience’s CETSA® (Cellular Thermal Shift Assay) technology. Please note that further assay optimization will be required in order to adapt the kit to your particular cell line and experimental conditions. A valid CETSA® licence from Pelago Bioscience or a single kit agreement is required for using the CETSA® technology.
false falseFor research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Checkpoint kinase 2 (CHK2) is a serine-threonine kinase and an integral member of the signaling cascade that controls the G1 cell cycle checkpoint. CHK2 is activated in response to DNA double-strand breaks and phosphorylates several modulators of cell cycle control including tumor suppressor proteins and prevents unchecked cell division. Mutations in CHK2 are linked to a wide range of cancers, such as breast, lung, prostate, kidney, and thyroid.
The AlphaLISA SureFire Ultra Total CHK2 assay is a sandwich immunoassay for the quantitative detection of Total CHK2 in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
Alpha SureFire kits can be used for:
檢測目標 | CHK2 |
---|---|
檢測技術 | Alpha |
自動化兼容 | Yes |
檢測方法 | Alpha |
實驗類型 | In vitro |
產品品牌名稱 | AlphaLISA SureFire Ultra |
運輸條件 | 藍冰 |
治療領域 | Oncology |
產品尺寸 | 50,000 Assay Points |
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automat ...
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...